Teva Pharmaceutical Industries (TEVA) Receives “Buy” Rating from Mizuho

Mizuho restated their buy rating on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a research report sent to investors on Friday. The firm currently has a $27.00 price target on the stock.

A number of other analysts have also weighed in on TEVA. Credit Suisse Group set a $23.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a buy rating in a report on Wednesday, April 4th. Vetr lowered shares of Teva Pharmaceutical Industries from a strong-buy rating to a buy rating and set a $21.73 target price for the company. in a report on Monday, March 12th. BTIG Research lowered shares of Teva Pharmaceutical Industries from a neutral rating to a sell rating and set a $17.00 target price for the company. in a report on Friday, February 2nd. Oppenheimer reiterated a hold rating on shares of Teva Pharmaceutical Industries in a report on Thursday, February 8th. Finally, Leerink Swann decreased their price target on shares of Teva Pharmaceutical Industries from $17.00 to $16.00 and set an underperform rating for the company in a research note on Friday, February 9th. Eleven equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of Hold and a consensus target price of $19.82.

Shares of Teva Pharmaceutical Industries stock traded up $0.11 during trading on Friday, reaching $17.82. 7,278,213 shares of the stock were exchanged, compared to its average volume of 8,136,091. The company has a current ratio of 0.86, a quick ratio of 0.58 and a debt-to-equity ratio of 1.91. The firm has a market cap of $18,008.89, a P/E ratio of 4.53, a P/E/G ratio of 1.54 and a beta of 0.67. Teva Pharmaceutical Industries has a 1 year low of $10.85 and a 1 year high of $33.82.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Thursday, February 8th. The company reported $0.91 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.77 by $0.14. The company had revenue of $5.46 billion during the quarter, compared to analyst estimates of $5.29 billion. Teva Pharmaceutical Industries had a negative net margin of 72.66% and a positive return on equity of 16.43%. Teva Pharmaceutical Industries’s revenue for the quarter was down 15.9% on a year-over-year basis. During the same period in the prior year, the business posted $1.38 earnings per share. research analysts forecast that Teva Pharmaceutical Industries will post 2.3 earnings per share for the current fiscal year.

In other Teva Pharmaceutical Industries news, EVP Mark Sabag sold 5,050 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $19.68, for a total transaction of $99,384.00. Following the completion of the transaction, the executive vice president now owns 44,517 shares of the company’s stock, valued at $876,094.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 10,734 shares of company stock valued at $204,795 in the last ninety days. Insiders own 7.10% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Calton & Associates Inc. bought a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $108,000. Global Financial Private Capital LLC bought a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $193,000. Wetherby Asset Management Inc. bought a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $197,000. Sigma Planning Corp bought a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $214,000. Finally, Comprehensive Portfolio Management LLC bought a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $226,000. 58.22% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This article was first posted by WKRB News and is the sole property of of WKRB News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.wkrb13.com/2018/04/21/teva-pharmaceutical-industries-teva-receives-buy-rating-from-mizuho.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply